Search all trials

Find therapies in clinical trials near you – page 12

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Neurodermatitis

Not recruiting

Investigational

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide

Contact Research Centre

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Not recruiting

Registered drugNo placebo

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Polycythaemia vera+1

Not recruiting

Registered drugNo placebo

Study of Ruxolitinib for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ruxolitinib

Contact Research Centre

Endometrial cancer

Not recruiting

Registered drug

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Daratumumab

Contact Research Centre

Breast cancer

Not recruiting

Registered drug

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Carfilzomib

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Investigational

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Inupadenant Hydrochloride

Contact Research Centre

Squamous cell carcinoma of the oral cavity+3

Not recruiting

Registered drugNo placebo

Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Graft versus host disease+1

Not recruiting

Registered drugNo placebo

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide

Contact Research Centre

Find therapies in clinical trials near you – page 12

208 trials match your criteria

Neurodermatitis

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Plasma cell myeloma

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Polycythaemia vera+1

Study of Ruxolitinib for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia

Endometrial cancer

Study on Durvalumab, Paclitaxel, Carboplatin, and Olaparib for Patients with Advanced or Recurrent Endometrial Cancer

Plasma cell myeloma

Comparison of allogeneic stem cell transplantation versus conventional therapy in patients with multiple myeloma who relapsed after first-line therapy

Plasma cell myeloma

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Breast cancer

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Plasma cell myeloma

Study on Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed High-Risk Multiple Myeloma Patients

Non-small cell lung cancer metastatic

Study on Inupadenant, Carboplatin, and Pemetrexed for Adults with Metastatic Non-Small Cell Lung Cancer After Immunotherapy

Squamous cell carcinoma of the oral cavity+3

Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

Graft versus host disease+1

Comparison of Post-Transplant Cyclophosphamide versus Anti-T Lymphocyte Immunoglobulin for Prevention of Graft versus Host Disease in Patients Receiving Unrelated Donor Transplantation

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.